Navigation Links
ExonHit is Honoured by the "Innovation Trophy" From The National Institute of Industrial Property (INPI)
Date:12/4/2008

PARIS, December 4 /PRNewswire-FirstCall/ -- ExonHit Therapeutics S.A. (Alternext: ALEHT), a drug and diagnostic discovery company, is pleased to announce today that it has been honoured by the INPI (National Institute of Industrial Property) during the last edition of its "Trophee de l'Innovation" (Innovation Trophy).

"Since its inception, ExonHit consistently made efforts to maintain and to protect the value of its intellectual property and in particular from its international patents. The discovery activities has allowed the Company to reach a leading intellectual property position, in the field of alternative splicing technologies as well as for drug candidates and innovative diagnostic solutions. This wide position is a true asset which results today in a portfolio of 204 international patents", declared Frederique Schlumberger, general counsel of ExonHit Therapeutics.

Loic Maurel, Chairman of the Executive Board of ExonHit Therapeutics, added : "I'm very proud to receive from the INPI this award in the name of all our teams of researchers who work for the company on a daily basis. This distinction is all the more symbolic in that it occurs at a key time of our development. Actually, in a few months, ExonHit is preparing the release of a first range of blood diagnostic tests for Alzheimer's disease in which all our collaborators have provided strong support to us. This future success would have never happened without a dedicated attention to defending our intellectual property. These patents are critical in our industry. They precede industrial successes and the creation of value of biotechnology companies like ExonHit ".

A ceremony took place this day in Paris, in the presence of Benoit Battistelli, General manager of the INPI, and Marc Antoine Jamet, President of the Union of the Manufacturers.

About ExonHit Therapeutics

http://www.exonhit.com

ExonHit Therapeutics is the world's leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases.

ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays, SpliceArrayTM family of products, that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers.

In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative diseases and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit.

Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The Company is listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005.

This press release includes only summary information and does not purport to be comprehensive. The projections, forecast and estimates of ExonHit Therapeutics which may be contained herein are for illustrative purposes only and are based on management's current views and assumptions. Such projections, forecast and estimates involve known and unknown risks and uncertainties, as described at Section 4.2 "Facteurs de risque" (Risk Factors) of the Document de Base available on ExonHit Therapeutics' website (http://www.exonhit.com), that may cause actual results, performance or events to differ materially from those anticipated in the summary information.

In addition, ExonHit Therapeutics, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.


'/>"/>
SOURCE ExonHit Therapeutics SA
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ExonHit Launches Mouse Genome SpliceArray(TM) for use in Human Disease Modeling Studies
2. Loic Maurel Joins Exonhit Therapeutics to Become CEO
3. ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics
4. Frederic Desdouits Appointed Member of the Supervisory Board of ExonHit Therapeutics
5. ExonHit Appoints a New Management Board
6. ExonHit Therapeutics - 2007 Financial Results
7. ExonHit Builds A New Organisation
8. ExonHit and bioMerieux Amend Their Strategic Partnership
9. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
10. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
11. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... 01, 2016 , ... ACEA Biosciences, Inc. announced today that it will be ... at the World Conference on Lung Cancer 2016, taking place in Vienna, Austria December ... clinical trials for AC0010 in patients with advanced non-small cell lung cancer harboring the ...
(Date:12/2/2016)... ... 2016 , ... DrugDev believes the only way to achieve real ... All three tenets were on display at the 2nd Annual DrugDev User Summit (hosted ... CRO and site organizations to discuss innovation and the future of clinical research. ...
(Date:12/2/2016)... PUNE, India , December 2, 2016 ... Billion by 2021, growing at a CAGR of 7.3% during the ... segment while hospitals and diagnostic laboratories segment accounted for the largest ... ... Complete report on global immunohistochemistry (IHC) market spread across 225 ...
(Date:11/30/2016)... 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... excited to announce the formation of EyGen, Ltd. ... ophthalmology assets through proof of concept. EyGen,s lead ... Portage Pharmaceuticals Limited and being developed for topical ... anterior segment diseases. This agent has the potential ...
Breaking Biology Technology:
(Date:11/24/2016)... -- Cercacor today introduced Ember TM Sport Premium ... measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion Index, ... approximately 30 seconds. Smaller than a smartphone, using only ... key data about their bodies to help monitor these ... Hemoglobin carries oxygen to muscles. When hemoglobin and ...
(Date:11/17/2016)... 17, 2016 Global Market Watch: Primarily ... Banks, Population-Based Banks and Academics) market is to witness a ... Biobanks shows the highest Compounded Annual Growth Rate (CAGR) of ... during the analysis period 2014-2020. North America ... followed by Europe at 9.56% respectively. ...
(Date:11/14/2016)... 14, 2016  xG Technology, Inc. ("xG" or the ... wireless communications for use in challenging operating environments, announced ... 2016. Management will hold a conference call to discuss ... Eastern Time (details below). Key Recent Accomplishments ... million binding agreement to acquire Vislink Communication Systems. The ...
Breaking Biology News(10 mins):